8-KShareholder Matters

BOSTON SCIENTIFIC CORP 8-K Report, Shareholder Vote Results (May 11, 2017)

Filed May 11, 2017For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on May 10, 2017, reporting the results of its 2017 Annual Meeting of Stockholders held on May 9, 2017. The filing indicates strong shareholder support for the company's board of directors, with all ten nominees elected for a one-year term. Additionally, shareholders provided advisory approval for the compensation of named executive officers and overwhelmingly supported holding these advisory votes on an annual basis. The company also announced the ratification of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year 2017. These outcomes suggest a stable corporate governance environment and continued shareholder confidence in the company's leadership and financial oversight mechanisms.

Key Highlights

  • 1All ten director nominees were overwhelmingly elected to the Board of Directors for a one-year term.
  • 2Shareholders approved, on an advisory basis, the compensation of Boston Scientific's Named Executive Officers.
  • 3Stockholders voted in favor of holding advisory votes on executive compensation on an annual basis, with a strong preference for 'One Year' frequency.
  • 4The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2017 was ratified by shareholders.
  • 5The Annual Meeting of Stockholders took place on May 9, 2017, at the company's headquarters in Marlborough, Massachusetts.

Frequently Asked Questions

This 8-K filing was made to report the official voting results from Boston Scientific Corporation's 2017 Annual Meeting of Stockholders, which covered several key corporate governance matters.

No, all ten director nominees were re-elected by a substantial majority, indicating continuity in board leadership for the upcoming year.

The advisory vote on executive compensation, often referred to as 'Say-on-Pay,' allows shareholders to voice their opinion on the compensation packages for the company's top executives. While non-binding, a strong approval indicates shareholder satisfaction with the compensation strategy.

Following the shareholder vote at the 2017 Annual Meeting, Boston Scientific will hold advisory votes on executive compensation on an annual basis, as this was the preferred frequency indicated by the voting results.